ArticleBiology2026
Corncob-Derived Xylo-Oligosaccharides Attenuate Acrylamide-Induced Gut-Liver Toxicity in Mice, Associated with Modulation of Gut Microbiota and SCFA Metabolism.
Article in Biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Acrylamide (AA) is a common foodborne toxicant formed during the thermal processing of starch-rich foods and poses significant risks to the gut-liver axis. Although corncob-derived xylo-oligosaccharides (XOS) have emerged as promising prebiotics with multiple bioactivities, their protective effects against foodborne toxicants have not been explored. This study investigated the ameliorative effects of dietary corncob-derived XOS on AA-induced gut-liver toxicity and the underlying mechanisms in mice. Female C57BL/6J mice were gavaged with AA and concurrently fed diets with or without 7.0% XOS for 7 weeks. The results showed that XOS effectively alleviated AA-induced gut-liver toxicity, as evidenced by attenuated intestinal and hepatic inflammation (decreased pro-inflammatory cytokines IL-6 in colon, TNF-α, and IL1-β in liver; increased anti-inflammatory IL-10 in colon and liver), restored intestinal barrier integrity (upregulated
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.